Risk Management

Laser Surgery for ROP

Click on the link below to access form.

Laser Surgery to treat ROP

Spanish translation TBD.

Articles on neurodevelopment after Avastin (bevacizumab) injection

OMIC and our ROP Task Force want to let you know of some studies on the effect of Avastin on the infant’s neurodevelopment. We have revised our ROP consent forms to address this research.

Pediatrics published a report[1] showing that the odds of severe neurodevelopmental disabilities was 3.1 times higher in infants treated with Avastin than those treated with laser. Another article[2] showed increased odds only in infants treated with both Avastin and laser.

Research is ongoing to determine if Avastin and other anti-VEGF drugs are safe. In the meantime, we all have to explain what we do know about these drugs to parents whose infants need treatment for ROP.


Please contact our confidential Risk Management Hotline if you need help developing or revising your protocols. You may email us at riskmanagement@omic.com or call 800-562-6642, option 4.



[1] Warren J, Luu TM, Superstein R, et al. Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity. Pediatrics. 2016; 137 (4): e20153218. http://pediatrics.aappublications.org/content/early/2016/03/16/peds.2015-3218

2 Lien R, Yu M-H, Hsu K-H, Liao P-J, Chen Y-P, Lai C-C, et al. (2016) Neurodevelopmental Outcomes in Infants with Retinopathy of Prematurity and Bevacizumab Treatment. PLoS ONE 11(1): e0148019. doi:10.1371/journal.pone.0148019. http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0148019

Please refer to OMIC's Copyright and Disclaimer regarding the contents on this website

Leave a comment

Six reasons OMIC is the best choice for ophthalmologists in America.

Best at defending claims.

An ophthalmologist pays nearly half a million dollars in premiums over the course of a career. Premium paid is directly related to a carrier’s claims experience. OMIC has a higher win rate taking tough cases to trial, full consent to settle (no hammer) clause, and access to the best experts. OMIC pays 25% less per claim than other carriers. As a result, OMIC has consistently maintained lower base rates than multispecialty carriers in the U.S.